Revvity (RVTY) Projected to Release Quarterly Earnings on Tuesday

Revvity (NYSE:RVTY) is expected to be issuing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Revvity to post earnings of $1.23 per share and revenue of $702.9570 million for the quarter. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 7:30 AM ET.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. The company had revenue of $711.12 million during the quarter, compared to the consensus estimate of $704.07 million. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.01 EPS. On average, analysts expect Revvity to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Revvity Stock Down 2.2%

RVTY stock opened at $108.04 on Tuesday. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $12.05 billion, a PE ratio of 51.69, a PEG ratio of 2.17 and a beta of 1.09. Revvity has a 1-year low of $81.22 and a 1-year high of $118.30. The business’s 50 day simple moving average is $105.15 and its 200 day simple moving average is $99.61.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 7th. Shareholders of record on Friday, July 17th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity’s dividend payout ratio (DPR) is currently 13.40%.

Institutional Trading of Revvity

Hedge funds have recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC bought a new stake in Revvity in the 2nd quarter valued at $32,000. MUFG Securities EMEA plc bought a new position in Revvity during the 2nd quarter worth $34,000. Headlands Technologies LLC bought a new position in Revvity during the 2nd quarter worth $49,000. Los Angeles Capital Management LLC acquired a new stake in shares of Revvity during the fourth quarter worth $51,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Revvity during the fourth quarter worth $72,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on RVTY shares. Wall Street Zen cut shares of Revvity from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. The Goldman Sachs Group dropped their price objective on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 14th. Weiss Ratings upgraded shares of Revvity from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $108.92.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.